E-Mail
(Singapore January 28, 2021 11:00 p.m. SPT/10:00 a.m. EST) Several leading international lung cancer researchers at a press briefing held by the International Association for the Study of Lung Cancer today, presented compelling new data revealing that factors of race, gender, sexual orientation and income continue to be significant barriers to those living with lung cancer. The press briefing is part of the IASLC s World Conference on Lung Cancer 2020 Singapore.
The press briefing is moderated by IASLC Communications Committee Chair Dr. Anne-Marie Baird, senior research fellow at Trinity College in Dublin and president of Lung Cancer Europe (LuCE), a nonprofit that aims to provide a voice for people impacted by lung cancer in Europe. Patient Research Advocate Jill Feldman, co-founder of the patient advocacy group, The EGFR Resisters, will contribute insights from the advocacy community s perspective.
The studies conducted jointly by the NIH -funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) showed that the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01, delivered intravenously once every eight weeks, was effective at preventing the acquisition of HIV strains that were sensitive to the antibody.
This was assessed by a laboratory test that measures a virus’ susceptibility to neutralization by an antibody.
Announcing the results during a press conference prior to the opening session of the meeting , Larry Corey, AMP Protocol Chair and Principal Investigator, HVTN Leadership Operations Center, based at the Fred Hutchinson Cancer Research Center, said the two proof-of-concept AMP studies demonstrated the concept that bnAb could actually prevent the acquisition of HIV infection.
TPG Real Estate Partners Alloy Properties snaps up life science campus in Bothell bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Getty Images
The start of this year’s HIV Research for Prevention Conference brings with it new findings show the potential of special antibodies to prevent HIV infection
This antibody can make people 75% less likely to become infected with a third of existing strains of HIV
Bhekisisa unpacks the study and breaks down the key concepts
There’s a new player in the HIV prevention field. Newly released results from the 4th HIV Research for Prevention Conference offers fresh insight into how the immune system can prevent HIV infection and serve as a guide for a potential, long-awaited HIV vaccine.
HIV antibody trial results offer proof of concept
Outcome of AMP shows feasibility of developing potent antibody combinations to block HIV March 17, 2021 • By Sabin Russell / Fred Hutch News Service Dr. Larry Corey, former president and director of Fred Hutchinson Cancer Research Center, was protocol chair of the Antibody Mediated Prevention trials and reported first results prior to the online HIV Research for Prevention scientific conference, which opened on Jan. 27. Photo by Robert Hood / Fred Hutch News Service
Editor s note: The story below was originally published on Jan. 26, 2021, upon release of the AMP results prior to an international HIV prevention conference. Details of the paired AMP trials have now been published in the March 18, 2021 edition of the